Source: International Congress 2015 – Case series and clinical conundrums in TB
Disease area: Respiratory infections

Abstract

Aim: Comparison of clinical manifestations and efficacy of treatment patients with MDR/XDR tuberculosis and different types of diabetes mellitus.Materials and methods: we investigated 53 patients with MDR/XDR tuberculosis (TB) in the age from 18 till 59 years (male - 38 and female - 15). In 30 patients were detected diabetes types 1 and in 23 patients - diabetes type 2. All patients were treated by individualized regimen. The efficacy of chemotherapy was estimated by the frequency and time of negativationof sputum and by reducing of cavity in lung.Results: It was established that the age of patients with diabetes type 1 was 18-39 years, and patients with diabetes type 2 - 40-59 years. Among patients both group more frequently observed infiltrative TB, fibro-cavernous TB and tuberculome. Severe TB intoxication frequently was detected among patients with diabetes type 1. Destruction in the lung was observed in all patients. The cavity with diameter of 2 cm were more frequently in patients with diabetes type 1, and 2-4 cm - in patients with diabetes type 2. M. tuberculosis (MTB) was detected in sputum of all patients. Quantity of MTB in sputum of patients with diabetes type 1 was few and in patients with diabetes type 2 – much. Conversion of sputum after 6 months of chemotherapy was detected in 78,5% and patients with diabetes type 1 and in 65,2% - with diabetes type 2. The frequency of closing cavities at 6 months of treatment was observed in 53,3% patients with diabetes type 1 and in 47,8% - with diabetes type 2.Conclusion. Clinical manifestations and efficacy of MDR/XDR TB in patients with type 1 and type 2 diabetes mellitus are different.


Rating:

Share or cite this content

Citations should be made in the following way:
Oksana Komissarova (Moscow, Russian Federation), Oksana Komissarova, Olga Konyayeva, Olga Berejnaya, Rizvan Abdullaev, Irina Vasilyeva. Clinical manifestations and efficacy MDR/XDR tuberculosis in patients with different type’s of diabetes mellitus. Eur Respir J 2015; 46: Suppl. 59, 2753

Member's Comments

No comment yet.

Related content which might interest you: Comparison of the clinical manifestations of tuberculosis in patients with different type’s of diabetes mellitus and without it Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe Year: 2016 Efficacy of treatment of MDR/XDR TB patients with diabetes mellitus Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Impact of diabetes mellitus on clinical parameters and treatment outcomes of diagnosed pulmonary tuberculosis patients Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 1 Year: 2014 Impact of diabetes mellitus on drug-resistant tuberculosis treatment outcomes in Georgia – Cohort study Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Prevalence of diabetes mellitus in new tuberculosis cases in Baghdad Source: International Congress 2015 – Epidemiology of TB: deaths, co-morbidities, migration and children Year: 2015 Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosis in an endemic area Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management II Year: 2013 Factors associated with severity of pulmonary tuberculosis and mortality in TB patients with diabetes mellitus Source: International Congress 2014 – Mycobacterium tuberculosis infection and disease: clinical epidemiology 1 Year: 2014 Effect of diabetes mellitus on the Time of mycobacterial clearance from sputum during the treatment of multi-drugs resistant tuberculosis Source: International Congress 2014 – Mycobacterium tuberculosis infection and disease: clinical epidemiology 2 Year: 2014 Screening of diabetes mellitus among new cases of tuberculosis Source: Annual Congress 2013 –Diagnostic features of tuberculosis I Year: 2013 Tuberculosis with diabetes mellitus: Does delayed sputum conversion always needs MDR evaluation? Source: International Congress 2014 – Mycobacterium tuberculosis infection and disease: clinical epidemiology 1 Year: 2014 A study of immunogenetic markers associated With tuberculosis and diabetes mellitus Source: Annual Congress 2013 –Diagnostic features of tuberculosis II Year: 2013 Addressing the tuberculosis (TB) and diabetes mellitus (DM) co-epidemic among TB patients in Luanda, Angola Source: International Congress 2016 – Epidemiological aspects of tuberculosis and other respiratory conditions: from lung cancer to late-onset Pompe's disease Year: 2016 Effectiveness of lung surgery in MDR TB patients with diabetes mellitus Source: International Congress 2016 – Open problems in thoracic surgery Year: 2016 Clinical characteristics and outcomes of pulmonary tuberculosis in patients with diabetes mellitus Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe Year: 2016 Clinical features of pulmonary tuberculosis in patients with diabetes mellitus Source: Annual Congress 2012 - Tuberculosis: clinical findings III Year: 2012 Latent mycobacterium tuberculosis infection among type 2 diabetes mellitus patients Source: International Congress 2015 – Screening strategies in TB Year: 2015 Plasma concentration of isoniazid and rifampin in new tuberculosis patients with and without diabetes mellitus Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Impact of diabetes on the presenting features of tuberculosis patients Source: International Congress 2014 – Mycobacterium tuberculosis infection and disease: clinical epidemiology 2 Year: 2014 Tuberculosis and diabetes mellitus: Treatment outcomes using directly observed therapy (DOT) Source: International Congress 2015 – Management of TB: a patient focus Year: 2015 Effectiveness of mesodiencephalic modulation in treatment of XDR TB patients with concomitant type II diabetes mellitus Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019